Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a Mitochondria-Targeting pill ease asthma in obesity?

NCT ID NCT04026711

First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 23 times

Summary

This early-phase trial tested whether MitoQ, a drug that targets cell powerhouses, can improve airway function in 47 obese adults with poorly controlled asthma. Participants took MitoQ or a placebo daily for 12 weeks. The main goal was to see if MitoQ reduces airway reactivity, a key asthma problem.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Duke University

    Durham, North Carolina, 27710, United States

  • University of Vermont

    Burlington, Vermont, 05405, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MitoQ (mitoquinol)

What this could lead to

If it works, this could point toward a new treatment option for obese people with hard-to-control asthma.

What could go wrong

This is a small, early-phase pilot study with only 47 participants. The results may not apply to all asthma patients, and MitoQ might not improve symptoms significantly.

Conditions

The condition(s) this trial relates to.

asthma Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.